CN114591425B - Specific antibody of new coronavirus S protein RBD region and preparation method and application thereof - Google Patents
Specific antibody of new coronavirus S protein RBD region and preparation method and application thereof Download PDFInfo
- Publication number
- CN114591425B CN114591425B CN202011419890.1A CN202011419890A CN114591425B CN 114591425 B CN114591425 B CN 114591425B CN 202011419890 A CN202011419890 A CN 202011419890A CN 114591425 B CN114591425 B CN 114591425B
- Authority
- CN
- China
- Prior art keywords
- nanobody
- seq
- antibody
- active fragment
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102100031673 Corneodesmosin Human genes 0.000 title claims abstract description 46
- 101710139375 Corneodesmosin Proteins 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 241000711573 Coronaviridae Species 0.000 title abstract description 27
- 239000012634 fragment Substances 0.000 claims abstract description 66
- 241000700605 Viruses Species 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 27
- 239000002773 nucleotide Substances 0.000 claims description 26
- 125000003729 nucleotide group Chemical group 0.000 claims description 26
- 210000004027 cell Anatomy 0.000 claims description 24
- 239000013604 expression vector Substances 0.000 claims description 22
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 238000012216 screening Methods 0.000 claims description 11
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 208000025721 COVID-19 Diseases 0.000 claims description 6
- 208000037847 SARS-CoV-2-infection Diseases 0.000 claims description 6
- 241001515965 unidentified phage Species 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 101710091045 Envelope protein Proteins 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 101710188315 Protein X Proteins 0.000 claims description 2
- 108091005774 SARS-CoV-2 proteins Proteins 0.000 claims description 2
- 102100021696 Syncytin-1 Human genes 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000002872 contrast media Substances 0.000 claims description 2
- 230000000155 isotopic effect Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000025171 antigen binding proteins Human genes 0.000 abstract description 39
- 108091000831 antigen binding proteins Proteins 0.000 abstract description 39
- 230000003053 immunization Effects 0.000 abstract description 12
- 210000000987 immune system Anatomy 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 239000002253 acid Substances 0.000 abstract description 2
- 239000003513 alkali Substances 0.000 abstract description 2
- 238000003759 clinical diagnosis Methods 0.000 abstract description 2
- 238000009792 diffusion process Methods 0.000 abstract description 2
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 230000004060 metabolic process Effects 0.000 abstract description 2
- 230000035699 permeability Effects 0.000 abstract description 2
- 238000005215 recombination Methods 0.000 abstract description 2
- 230000006798 recombination Effects 0.000 abstract description 2
- 230000009466 transformation Effects 0.000 abstract description 2
- 239000000427 antigen Substances 0.000 description 63
- 102000036639 antigens Human genes 0.000 description 63
- 108091007433 antigens Proteins 0.000 description 63
- 150000001413 amino acids Chemical group 0.000 description 38
- 108020004414 DNA Proteins 0.000 description 17
- 241001416177 Vicugna pacos Species 0.000 description 16
- 241000588724 Escherichia coli Species 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 9
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 9
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 210000005259 peripheral blood Anatomy 0.000 description 8
- 239000011886 peripheral blood Substances 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 6
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 6
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 6
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 6
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 6
- 108010008355 arginyl-glutamine Proteins 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 6
- SLKLLQWZQHXYSV-CIUDSAMLSA-N Asn-Ala-Lys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O SLKLLQWZQHXYSV-CIUDSAMLSA-N 0.000 description 5
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 5
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 5
- 108010090333 leucyl-lysyl-proline Proteins 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- KIUYPHAMDKDICO-WHFBIAKZSA-N Ala-Asp-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O KIUYPHAMDKDICO-WHFBIAKZSA-N 0.000 description 4
- IPZQNYYAYVRKKK-FXQIFTODSA-N Ala-Pro-Ala Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IPZQNYYAYVRKKK-FXQIFTODSA-N 0.000 description 4
- 235000002198 Annona diversifolia Nutrition 0.000 description 4
- MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 4
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 4
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 4
- ZFBBMCKQSNJZSN-AUTRQRHGSA-N Gln-Val-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZFBBMCKQSNJZSN-AUTRQRHGSA-N 0.000 description 4
- DTPOVRRYXPJJAZ-FJXKBIBVSA-N Gly-Arg-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N DTPOVRRYXPJJAZ-FJXKBIBVSA-N 0.000 description 4
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 4
- WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 4
- YWCJXQKATPNPOE-UKJIMTQDSA-N Ile-Val-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N YWCJXQKATPNPOE-UKJIMTQDSA-N 0.000 description 4
- 241000282842 Lama glama Species 0.000 description 4
- 241000880493 Leptailurus serval Species 0.000 description 4
- AXZGZMGRBDQTEY-SRVKXCTJSA-N Leu-Gln-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O AXZGZMGRBDQTEY-SRVKXCTJSA-N 0.000 description 4
- CNGOEHJCLVCJHN-SRVKXCTJSA-N Lys-Pro-Glu Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O CNGOEHJCLVCJHN-SRVKXCTJSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 4
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 4
- ZENDEDYRYVHBEG-SRVKXCTJSA-N Phe-Asp-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 ZENDEDYRYVHBEG-SRVKXCTJSA-N 0.000 description 4
- IAOZOFPONWDXNT-IXOXFDKPSA-N Phe-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IAOZOFPONWDXNT-IXOXFDKPSA-N 0.000 description 4
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 4
- QKWYXRPICJEQAJ-KJEVXHAQSA-N Pro-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2)O QKWYXRPICJEQAJ-KJEVXHAQSA-N 0.000 description 4
- QEDMOZUJTGEIBF-FXQIFTODSA-N Ser-Arg-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O QEDMOZUJTGEIBF-FXQIFTODSA-N 0.000 description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 4
- SLOYNOMYOAOUCX-BVSLBCMMSA-N Trp-Phe-Arg Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SLOYNOMYOAOUCX-BVSLBCMMSA-N 0.000 description 4
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 4
- 108010045023 alanyl-prolyl-tyrosine Proteins 0.000 description 4
- 108010059459 arginyl-threonyl-phenylalanine Proteins 0.000 description 4
- 108010047857 aspartylglycine Proteins 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 4
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 4
- SKTGPBFTMNLIHQ-KKUMJFAQSA-N Arg-Glu-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SKTGPBFTMNLIHQ-KKUMJFAQSA-N 0.000 description 3
- KRQSPVKUISQQFS-FJXKBIBVSA-N Arg-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N KRQSPVKUISQQFS-FJXKBIBVSA-N 0.000 description 3
- BCADFFUQHIMQAA-KKHAAJSZSA-N Asn-Thr-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O BCADFFUQHIMQAA-KKHAAJSZSA-N 0.000 description 3
- CQMFNTVQVLQRLT-JHEQGTHGSA-N Gly-Thr-Gln Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O CQMFNTVQVLQRLT-JHEQGTHGSA-N 0.000 description 3
- MVJRBCJCRYGCKV-GVXVVHGQSA-N Leu-Val-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O MVJRBCJCRYGCKV-GVXVVHGQSA-N 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- JXQVYPWVGUOIDV-MXAVVETBSA-N Phe-Ser-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JXQVYPWVGUOIDV-MXAVVETBSA-N 0.000 description 3
- YOPQYBJJNSIQGZ-JNPHEJMOSA-N Thr-Tyr-Tyr Chemical compound C([C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 YOPQYBJJNSIQGZ-JNPHEJMOSA-N 0.000 description 3
- SVGAWGVHFIYAEE-JSGCOSHPSA-N Trp-Gly-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 SVGAWGVHFIYAEE-JSGCOSHPSA-N 0.000 description 3
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 3
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000010923 batch production Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 108010078144 glutaminyl-glycine Proteins 0.000 description 3
- 108010084389 glycyltryptophan Proteins 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 108010038745 tryptophylglycine Proteins 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- LGQPPBQRUBVTIF-JBDRJPRFSA-N Ala-Ala-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LGQPPBQRUBVTIF-JBDRJPRFSA-N 0.000 description 2
- JBVSSSZFNTXJDX-YTLHQDLWSA-N Ala-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N JBVSSSZFNTXJDX-YTLHQDLWSA-N 0.000 description 2
- BLTRAARCJYVJKV-QEJZJMRPSA-N Ala-Lys-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(O)=O BLTRAARCJYVJKV-QEJZJMRPSA-N 0.000 description 2
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 2
- OQCWXQJLCDPRHV-UWVGGRQHSA-N Arg-Gly-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O OQCWXQJLCDPRHV-UWVGGRQHSA-N 0.000 description 2
- SYAUZLVLXCDRSH-IUCAKERBSA-N Arg-Gly-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N SYAUZLVLXCDRSH-IUCAKERBSA-N 0.000 description 2
- SVABRQFIHCSNCI-FOHZUACHSA-N Asp-Gly-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O SVABRQFIHCSNCI-FOHZUACHSA-N 0.000 description 2
- ZKAOJVJQGVUIIU-GUBZILKMSA-N Asp-Pro-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ZKAOJVJQGVUIIU-GUBZILKMSA-N 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 2
- HHWQMFIGMMOVFK-WDSKDSINSA-N Gln-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O HHWQMFIGMMOVFK-WDSKDSINSA-N 0.000 description 2
- HNAUFGBKJLTWQE-IFFSRLJSSA-N Gln-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)N)O HNAUFGBKJLTWQE-IFFSRLJSSA-N 0.000 description 2
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 2
- LHRXAHLCRMQBGJ-RYUDHWBXSA-N Gly-Glu-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CN LHRXAHLCRMQBGJ-RYUDHWBXSA-N 0.000 description 2
- GMTXWRIDLGTVFC-IUCAKERBSA-N Gly-Lys-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMTXWRIDLGTVFC-IUCAKERBSA-N 0.000 description 2
- CSMYMGFCEJWALV-WDSKDSINSA-N Gly-Ser-Gln Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O CSMYMGFCEJWALV-WDSKDSINSA-N 0.000 description 2
- VNNRLUNBJSWZPF-ZKWXMUAHSA-N Gly-Ser-Ile Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VNNRLUNBJSWZPF-ZKWXMUAHSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- YBHKCXNNNVDYEB-SPOWBLRKSA-N Ile-Trp-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CO)C(=O)O)N YBHKCXNNNVDYEB-SPOWBLRKSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- VCSBGUACOYUIGD-CIUDSAMLSA-N Leu-Asn-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VCSBGUACOYUIGD-CIUDSAMLSA-N 0.000 description 2
- DLFAACQHIRSQGG-CIUDSAMLSA-N Leu-Asp-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O DLFAACQHIRSQGG-CIUDSAMLSA-N 0.000 description 2
- YWFZWQKWNDOWPA-XIRDDKMYSA-N Leu-Trp-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(O)=O YWFZWQKWNDOWPA-XIRDDKMYSA-N 0.000 description 2
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- MVIJMIZJPHQGEN-IHRRRGAJSA-N Phe-Ser-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@H](CO)NC(=O)[C@@H]([NH3+])CC1=CC=CC=C1 MVIJMIZJPHQGEN-IHRRRGAJSA-N 0.000 description 2
- MWMKFWJYRRGXOR-ZLUOBGJFSA-N Ser-Ala-Asn Chemical compound N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CC(N)=O)C)CO MWMKFWJYRRGXOR-ZLUOBGJFSA-N 0.000 description 2
- INCNPLPRPOYTJI-JBDRJPRFSA-N Ser-Cys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N INCNPLPRPOYTJI-JBDRJPRFSA-N 0.000 description 2
- VGQVAVQWKJLIRM-FXQIFTODSA-N Ser-Ser-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O VGQVAVQWKJLIRM-FXQIFTODSA-N 0.000 description 2
- YEDSOSIKVUMIJE-DCAQKATOSA-N Ser-Val-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O YEDSOSIKVUMIJE-DCAQKATOSA-N 0.000 description 2
- KZUJCMPVNXOBAF-LKXGYXEUSA-N Thr-Cys-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(O)=O KZUJCMPVNXOBAF-LKXGYXEUSA-N 0.000 description 2
- GFRIEEKFXOVPIR-RHYQMDGZSA-N Thr-Pro-Lys Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O GFRIEEKFXOVPIR-RHYQMDGZSA-N 0.000 description 2
- FWTFAZKJORVTIR-VZFHVOOUSA-N Thr-Ser-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O FWTFAZKJORVTIR-VZFHVOOUSA-N 0.000 description 2
- HIINQLBHPIQYHN-JTQLQIEISA-N Tyr-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HIINQLBHPIQYHN-JTQLQIEISA-N 0.000 description 2
- OJCISMMNNUNNJA-BZSNNMDCSA-N Tyr-Tyr-Asp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(O)=O)C(O)=O)C1=CC=C(O)C=C1 OJCISMMNNUNNJA-BZSNNMDCSA-N 0.000 description 2
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 2
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 2
- 108010013835 arginine glutamate Proteins 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108010050475 glycyl-leucyl-tyrosine Proteins 0.000 description 2
- 108010089804 glycyl-threonine Proteins 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108010017949 tyrosyl-glycyl-glycine Proteins 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 108010027345 wheylin-1 peptide Proteins 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- BUDNAJYVCUHLSV-ZLUOBGJFSA-N Ala-Asp-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O BUDNAJYVCUHLSV-ZLUOBGJFSA-N 0.000 description 1
- PUBLUECXJRHTBK-ACZMJKKPSA-N Ala-Glu-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O PUBLUECXJRHTBK-ACZMJKKPSA-N 0.000 description 1
- VNYMOTCMNHJGTG-JBDRJPRFSA-N Ala-Ile-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O VNYMOTCMNHJGTG-JBDRJPRFSA-N 0.000 description 1
- LXAARTARZJJCMB-CIQUZCHMSA-N Ala-Ile-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LXAARTARZJJCMB-CIQUZCHMSA-N 0.000 description 1
- OMDNCNKNEGFOMM-BQBZGAKWSA-N Ala-Met-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)NCC(O)=O OMDNCNKNEGFOMM-BQBZGAKWSA-N 0.000 description 1
- AWNAEZICPNGAJK-FXQIFTODSA-N Ala-Met-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O AWNAEZICPNGAJK-FXQIFTODSA-N 0.000 description 1
- SYIFFFHSXBNPMC-UWJYBYFXSA-N Ala-Ser-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N SYIFFFHSXBNPMC-UWJYBYFXSA-N 0.000 description 1
- VHAQSYHSDKERBS-XPUUQOCRSA-N Ala-Val-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O VHAQSYHSDKERBS-XPUUQOCRSA-N 0.000 description 1
- REWSWYIDQIELBE-FXQIFTODSA-N Ala-Val-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O REWSWYIDQIELBE-FXQIFTODSA-N 0.000 description 1
- ZDILXFDENZVOTL-BPNCWPANSA-N Ala-Val-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZDILXFDENZVOTL-BPNCWPANSA-N 0.000 description 1
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- MFAMTAVAFBPXDC-LPEHRKFASA-N Arg-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O MFAMTAVAFBPXDC-LPEHRKFASA-N 0.000 description 1
- PBSOQGZLPFVXPU-YUMQZZPRSA-N Arg-Glu-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O PBSOQGZLPFVXPU-YUMQZZPRSA-N 0.000 description 1
- NKBQZKVMKJJDLX-SRVKXCTJSA-N Arg-Glu-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NKBQZKVMKJJDLX-SRVKXCTJSA-N 0.000 description 1
- JEOCWTUOMKEEMF-RHYQMDGZSA-N Arg-Leu-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JEOCWTUOMKEEMF-RHYQMDGZSA-N 0.000 description 1
- VKCOHFFSTKCXEQ-OLHMAJIHSA-N Asn-Asn-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VKCOHFFSTKCXEQ-OLHMAJIHSA-N 0.000 description 1
- JBDLMLZNDRLDIX-HJGDQZAQSA-N Asn-Thr-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O JBDLMLZNDRLDIX-HJGDQZAQSA-N 0.000 description 1
- YNQIDCRRTWGHJD-ZLUOBGJFSA-N Asp-Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(O)=O YNQIDCRRTWGHJD-ZLUOBGJFSA-N 0.000 description 1
- WNGZKSVJFDZICU-XIRDDKMYSA-N Asp-Leu-Trp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)N WNGZKSVJFDZICU-XIRDDKMYSA-N 0.000 description 1
- IOXWDLNHXZOXQP-FXQIFTODSA-N Asp-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N IOXWDLNHXZOXQP-FXQIFTODSA-N 0.000 description 1
- QSFHZPQUAAQHAQ-CIUDSAMLSA-N Asp-Ser-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O QSFHZPQUAAQHAQ-CIUDSAMLSA-N 0.000 description 1
- JSHWXQIZOCVWIA-ZKWXMUAHSA-N Asp-Ser-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JSHWXQIZOCVWIA-ZKWXMUAHSA-N 0.000 description 1
- IWLZBRTUIVXZJD-OLHMAJIHSA-N Asp-Thr-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O IWLZBRTUIVXZJD-OLHMAJIHSA-N 0.000 description 1
- UXRVDHVARNBOIO-QSFUFRPTSA-N Asp-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)N UXRVDHVARNBOIO-QSFUFRPTSA-N 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- VYOILACOFPPNQH-UMNHJUIQSA-N Gln-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N VYOILACOFPPNQH-UMNHJUIQSA-N 0.000 description 1
- RDDSZZJOKDVPAE-ACZMJKKPSA-N Glu-Asn-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O RDDSZZJOKDVPAE-ACZMJKKPSA-N 0.000 description 1
- RDPOETHPAQEGDP-ACZMJKKPSA-N Glu-Asp-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O RDPOETHPAQEGDP-ACZMJKKPSA-N 0.000 description 1
- MTAOBYXRYJZRGQ-WDSKDSINSA-N Glu-Gly-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MTAOBYXRYJZRGQ-WDSKDSINSA-N 0.000 description 1
- HILMIYALTUQTRC-XVKPBYJWSA-N Glu-Gly-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HILMIYALTUQTRC-XVKPBYJWSA-N 0.000 description 1
- ZGKXAUIVGIBISK-SZMVWBNQSA-N Glu-His-Trp Chemical compound N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O ZGKXAUIVGIBISK-SZMVWBNQSA-N 0.000 description 1
- OCJRHJZKGGSPRW-IUCAKERBSA-N Glu-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O OCJRHJZKGGSPRW-IUCAKERBSA-N 0.000 description 1
- DMYACXMQUABZIQ-NRPADANISA-N Glu-Ser-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O DMYACXMQUABZIQ-NRPADANISA-N 0.000 description 1
- LJPIRKICOISLKN-WHFBIAKZSA-N Gly-Ala-Ser Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O LJPIRKICOISLKN-WHFBIAKZSA-N 0.000 description 1
- NZAFOTBEULLEQB-WDSKDSINSA-N Gly-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)CN NZAFOTBEULLEQB-WDSKDSINSA-N 0.000 description 1
- QGZSAHIZRQHCEQ-QWRGUYRKSA-N Gly-Asp-Tyr Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QGZSAHIZRQHCEQ-QWRGUYRKSA-N 0.000 description 1
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 1
- HDNXXTBKOJKWNN-WDSKDSINSA-N Gly-Glu-Asn Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O HDNXXTBKOJKWNN-WDSKDSINSA-N 0.000 description 1
- LOEANKRDMMVOGZ-YUMQZZPRSA-N Gly-Lys-Asp Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CC(O)=O)C(O)=O LOEANKRDMMVOGZ-YUMQZZPRSA-N 0.000 description 1
- FHQRLHFYVZAQHU-IUCAKERBSA-N Gly-Lys-Gln Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O FHQRLHFYVZAQHU-IUCAKERBSA-N 0.000 description 1
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 1
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- MUENHEQLLUDKSC-PMVMPFDFSA-N His-Tyr-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CNC=N1 MUENHEQLLUDKSC-PMVMPFDFSA-N 0.000 description 1
- TZCGZYWNIDZZMR-UHFFFAOYSA-N Ile-Arg-Ala Natural products CCC(C)C(N)C(=O)NC(C(=O)NC(C)C(O)=O)CCCN=C(N)N TZCGZYWNIDZZMR-UHFFFAOYSA-N 0.000 description 1
- RQJUKVXWAKJDBW-SVSWQMSJSA-N Ile-Ser-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N RQJUKVXWAKJDBW-SVSWQMSJSA-N 0.000 description 1
- ZTLGVASZOIKNIX-DCAQKATOSA-N Leu-Gln-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZTLGVASZOIKNIX-DCAQKATOSA-N 0.000 description 1
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 1
- LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 description 1
- VGPCJSXPPOQPBK-YUMQZZPRSA-N Leu-Gly-Ser Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O VGPCJSXPPOQPBK-YUMQZZPRSA-N 0.000 description 1
- FAELBUXXFQLUAX-AJNGGQMLSA-N Leu-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C FAELBUXXFQLUAX-AJNGGQMLSA-N 0.000 description 1
- PPQRKXHCLYCBSP-IHRRRGAJSA-N Leu-Leu-Met Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)O)N PPQRKXHCLYCBSP-IHRRRGAJSA-N 0.000 description 1
- RTIRBWJPYJYTLO-MELADBBJSA-N Leu-Lys-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N RTIRBWJPYJYTLO-MELADBBJSA-N 0.000 description 1
- WXZOHBVPVKABQN-DCAQKATOSA-N Leu-Met-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)O)N WXZOHBVPVKABQN-DCAQKATOSA-N 0.000 description 1
- JMNRXRPBHFGXQX-GUBZILKMSA-N Lys-Ser-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O JMNRXRPBHFGXQX-GUBZILKMSA-N 0.000 description 1
- 101710145006 Lysis protein Proteins 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- CAODKDAPYGUMLK-FXQIFTODSA-N Met-Asn-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O CAODKDAPYGUMLK-FXQIFTODSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- LZHHZYDPMZEMRX-STQMWFEESA-N Pro-Tyr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O LZHHZYDPMZEMRX-STQMWFEESA-N 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- LVVBAKCGXXUHFO-ZLUOBGJFSA-N Ser-Ala-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O LVVBAKCGXXUHFO-ZLUOBGJFSA-N 0.000 description 1
- VXYQOFXBIXKPCX-BQBZGAKWSA-N Ser-Met-Gly Chemical compound CSCC[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CO)N VXYQOFXBIXKPCX-BQBZGAKWSA-N 0.000 description 1
- PPCZVWHJWJFTFN-ZLUOBGJFSA-N Ser-Ser-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPCZVWHJWJFTFN-ZLUOBGJFSA-N 0.000 description 1
- AXKJPUBALUNJEO-UBHSHLNASA-N Ser-Trp-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(O)=O AXKJPUBALUNJEO-UBHSHLNASA-N 0.000 description 1
- MFQMZDPAZRZAPV-NAKRPEOUSA-N Ser-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N MFQMZDPAZRZAPV-NAKRPEOUSA-N 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- DWYAUVCQDTZIJI-VZFHVOOUSA-N Thr-Ala-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DWYAUVCQDTZIJI-VZFHVOOUSA-N 0.000 description 1
- OHAJHDJOCKKJLV-LKXGYXEUSA-N Thr-Asp-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O OHAJHDJOCKKJLV-LKXGYXEUSA-N 0.000 description 1
- DKDHTRVDOUZZTP-IFFSRLJSSA-N Thr-Gln-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O DKDHTRVDOUZZTP-IFFSRLJSSA-N 0.000 description 1
- XPNSAQMEAVSQRD-FBCQKBJTSA-N Thr-Gly-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)NCC(O)=O XPNSAQMEAVSQRD-FBCQKBJTSA-N 0.000 description 1
- KRGDDWVBBDLPSJ-CUJWVEQBSA-N Thr-His-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O KRGDDWVBBDLPSJ-CUJWVEQBSA-N 0.000 description 1
- YDWLCDQXLCILCZ-BWAGICSOSA-N Thr-His-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O YDWLCDQXLCILCZ-BWAGICSOSA-N 0.000 description 1
- URPSJRMWHQTARR-MBLNEYKQSA-N Thr-Ile-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O URPSJRMWHQTARR-MBLNEYKQSA-N 0.000 description 1
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 1
- BPGDJSUFQKWUBK-KJEVXHAQSA-N Thr-Val-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 BPGDJSUFQKWUBK-KJEVXHAQSA-N 0.000 description 1
- MHNHRNHJMXAVHZ-AAEUAGOBSA-N Trp-Asn-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)O)N MHNHRNHJMXAVHZ-AAEUAGOBSA-N 0.000 description 1
- UIDJDMVRDUANDL-BVSLBCMMSA-N Trp-Tyr-Arg Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UIDJDMVRDUANDL-BVSLBCMMSA-N 0.000 description 1
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 1
- CDRYEAWHKJSGAF-BPNCWPANSA-N Tyr-Ala-Met Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O CDRYEAWHKJSGAF-BPNCWPANSA-N 0.000 description 1
- DXYWRYQRKPIGGU-BPNCWPANSA-N Tyr-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DXYWRYQRKPIGGU-BPNCWPANSA-N 0.000 description 1
- YRBHLWWGSSQICE-IHRRRGAJSA-N Tyr-Asp-Met Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O YRBHLWWGSSQICE-IHRRRGAJSA-N 0.000 description 1
- ZAGPDPNPWYPEIR-SRVKXCTJSA-N Tyr-Cys-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O ZAGPDPNPWYPEIR-SRVKXCTJSA-N 0.000 description 1
- OLWFDNLLBWQWCP-STQMWFEESA-N Tyr-Gly-Met Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](CCSC)C(O)=O OLWFDNLLBWQWCP-STQMWFEESA-N 0.000 description 1
- QAYSODICXVZUIA-WLTAIBSBSA-N Tyr-Gly-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O QAYSODICXVZUIA-WLTAIBSBSA-N 0.000 description 1
- QSFJHIRIHOJRKS-ULQDDVLXSA-N Tyr-Leu-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QSFJHIRIHOJRKS-ULQDDVLXSA-N 0.000 description 1
- CNNVVEPJTFOGHI-ACRUOGEOSA-N Tyr-Lys-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CNNVVEPJTFOGHI-ACRUOGEOSA-N 0.000 description 1
- XYBNMHRFAUKPAW-IHRRRGAJSA-N Tyr-Ser-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(C=C1)O)N XYBNMHRFAUKPAW-IHRRRGAJSA-N 0.000 description 1
- NZBSVMQZQMEUHI-WZLNRYEVSA-N Tyr-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N NZBSVMQZQMEUHI-WZLNRYEVSA-N 0.000 description 1
- GAKBTSMAPGLQFA-JNPHEJMOSA-N Tyr-Thr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 GAKBTSMAPGLQFA-JNPHEJMOSA-N 0.000 description 1
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 1
- KSGKJSFPWSMJHK-JNPHEJMOSA-N Tyr-Tyr-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KSGKJSFPWSMJHK-JNPHEJMOSA-N 0.000 description 1
- VXDSPJJQUQDCKH-UKJIMTQDSA-N Val-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N VXDSPJJQUQDCKH-UKJIMTQDSA-N 0.000 description 1
- DIOSYUIWOQCXNR-ONGXEEELSA-N Val-Lys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O DIOSYUIWOQCXNR-ONGXEEELSA-N 0.000 description 1
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 1
- IECQJCJNPJVUSB-IHRRRGAJSA-N Val-Tyr-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(O)=O IECQJCJNPJVUSB-IHRRRGAJSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 108700010904 coronavirus proteins Proteins 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 108010080575 glutamyl-aspartyl-alanine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
Abstract
The present invention relates to an antigen binding protein, antibody or antibody active fragment obtained by immunizing camelid with RBD region of S protein of SARS-Cov-2. The invention screens, identifies and prepares the antibody of the RBD region of the S protein on the surface of the new coronavirus by relying on the immune system of the camelid, and the obtained antibody has the advantages of strong specificity, high affinity, small relative molecular mass, high solubility, strong tissue permeability, good distribution, rapid diffusion and metabolism, simple structure, easy genetic engineering transformation, simple humanization, high stability, acid and alkali pH resistance, high temperature resistance, lower mass production cost, easy large-scale recombination preparation and potential clinical diagnosis and treatment value.
Description
Technical Field
The invention relates to the field of biotechnology, in particular to a specific antibody of a new coronavirus S protein RBD region and a preparation method and application thereof.
Background
Antibodies are proteins secreted primarily by plasma cells and used by the immune system to identify and neutralize foreign substances, called antigens, such as bacteria, viruses, and the like. The binding of antibodies to antigens relies entirely on noncovalent interactions, and this specific binding mechanism allows the antibodies to capture foreign microorganisms as well as infected cells, further induce other immune mechanisms to attack them, or directly neutralize their targets. Antibodies and antibody-related products have been widely used in the fields of life science and medicine, and many experimental techniques derived based on antigen-antibody specific binding have laid important foundations for scientific research and clinical treatment, such as immunodiagnosis, immunoblotting, enzyme-linked immunosorbent assay, flow cytometry and the like.
The new coronavirus causes epidemic situation to spread rapidly in the world. In the process of researching new coronavirus, the antibody is a very important research tool, and has great value and significance for patient diagnosis, virus analysis and research and the like. Since the onset of an outbreak, development of antibodies specific for new coronavirus has begun around the world. According to recent literature reports, murine mabs that specifically recognize and bind to the S protein on the surface of new coronaviruses have been developed by several research organizations in the world, and their main technical schemes are: (1) Preparing new coronavirus antigen, such as inactivated new coronavirus particles, separating and extracting different components of new coronavirus, etc.; (2) Injecting the antigen into a rat or a mouse, and generating an antibody by means of an immune system of the animal; (3) Collecting animal blood, separating, extracting serum, and further separating to obtain components containing specific antibody.
The above-mentioned technology for producing antibodies against S protein on the surface of a new coronavirus based on the immune system of an animal such as a mouse, and separating and extracting the antibodies has the following disadvantages: (1) antibodies have limited specificity: the S protein has a large structure and complex space folding, the traditional mouse monoclonal antibody is difficult to recognize the complex space structure of the S surface, and researchers are difficult to obtain antibodies aiming at each structural domain; (2) poor stability of the antibody: the mouse monoclonal antibody can maintain the characteristics of the concentration, the specificity and the like of the antibody only by storing, transporting, testing, verifying and the like at low temperature (4 ℃), and is not beneficial to the development of large-scale application to research; (3) the scale batch production of finished products is high: the mouse monoclonal antibody is a full-length immunoglobulin, needs to be separated, purified and lifted after being subjected to recombinant expression in expensive expression systems such as mammalian cells and the like, is complex to operate, has high cost, and is not beneficial to large-scale batch production.
Disclosure of Invention
The invention overcomes the defects of the prior art, designs and implements an effective and feasible antibody screening and preparation technical scheme, obtains the antibody which can specifically recognize and combine with the RBD region of the S protein on the surface of the new coronavirus, and performs batch production preparation and application thereof.
The above object of the present invention is achieved by the following embodiments.
In a first aspect, the present invention provides an antigen binding protein, antibody or antibody active fragment obtained by immunizing a camelid with the S protein RBD region of SARS-Cov-2.
In some embodiments, the camelid is selected from dromedary, bactrian, llama, alpaca and llama, preferably alpaca.
In some embodiments, the antibody is a nanobody and the antibody active fragment is a nanobody active fragment.
In some embodiments, the antibody is a monoclonal antibody or a polyclonal antibody.
In some embodiments, the antigen binding protein, antibody or antibody active fragment binds to the S protein RBD region of SARS-Cov-2 at a kd value of 3000nM or less, preferably 1500nM or less, more preferably 600nM or less, more preferably 100nM or less, more preferably 10nM or less, more preferably 5nM or less, more preferably 1nM or less.
In some embodiments, the S protein RBD region of SARS-Cov-2 has an amino acid sequence as set forth in SEQ ID NO 1. Further preferably, the S protein RBD region of SARS-Cov-2 is prepared by a method comprising the following steps: connecting the nucleotide sequence of the S protein RBD region of the SARS-Cov-2 with the nucleotide sequence of the coding transmembrane structure in series, and constructing a vector plasmid; the vector plasmid is transfected into a eukaryotic cell line for expression, so that an S protein RBD region of SARS-Cov-2 is displayed outside a cell membrane in the form of a transmembrane protein.
In a second aspect, the present invention provides a method of constructing an antibody library, the method comprising the steps of:
(1) Immunizing camelid with S protein RBD region of SARS-Cov-2 as antigen, collecting peripheral venous blood of immunized animal, and separating to obtain lymphocyte;
(2) Extracting total mRNA of the lymphocytes, performing reverse transcription on the total mRNA into cDNA, and amplifying the cDNA;
(3) And inserting the DNA obtained by amplification into a virus expression vector, transforming into bacteria, and collecting bacterial colonies to obtain an antibody library.
In some embodiments, the camelid is selected from dromedary, bactrian, llama, alpaca and llama, preferably alpaca.
In some embodiments, the immunizing of step (1) is performed by subcutaneous injection. The number of immunizations is preferably 3 to 5. The venous peripheral blood is preferably collected before and after the last immunization, respectively.
In some embodiments, the viral expression vector of step (3) is a phage expression vector.
In some embodiments, the bacterium of step (3) is escherichia coli.
In a third aspect, the present invention provides an antibody library obtained by the above method for constructing an antibody library, or a polyclonal antibody produced by expression of the antibody library.
In a fourth aspect, the present invention provides a method of constructing an antigen-specific antibody library, the method comprising the steps of: screening the antibody library of the third aspect to obtain an antigen-specific antibody library.
In some embodiments, the method of constructing an antigen-specific antibody library comprises the steps of:
(i) Culturing the antibody library to release viruses;
(ii) Incubating the virus with an antigen, removing the virus non-specifically bound to the antigen, and retaining the virus specifically bound to the antigen;
(iii) Infecting bacteria with the virus specifically bound to the antigen, collecting colonies, and obtaining an antigen-specific antibody library.
In some embodiments, the bacterium of step (iii) is escherichia coli.
In a fifth aspect, the present invention provides an antigen-specific antibody library obtained by the above-described method for constructing an antigen-specific antibody library, or a polyclonal antibody specifically binding to an antigen produced by expression of the antigen-specific antibody library.
In a sixth aspect, the present invention provides a method of preparing an antigen binding protein, antibody or antibody active fragment, said method comprising the steps of: screening the antibody library of the third aspect to obtain an antigen binding protein, an antibody or an antibody active fragment that specifically binds to an antigen.
In some embodiments, the method of making an antigen binding protein, antibody or antibody active fragment comprises the steps of:
(a) Culturing the antibody library to release viruses;
(b) Incubating the virus with an antigen, removing the virus non-specifically bound to the antigen, and retaining the virus specifically bound to the antigen;
(c) Infecting bacteria with the virus specifically bound to the antigen, smearing the infected bacteria on a plate culture medium for culture, and selecting a single colony.
In some embodiments, the bacterium of step (c) is escherichia coli.
In some embodiments, the single colony may be expanded for culture prior to antigen-specific binding identification.
In some embodiments, the single colony may be expanded and then subjected to step (d): the DNA is extracted, transformed into a host cell and expressed to obtain a monoclonal antibody.
In a seventh aspect, the present invention provides an antigen-binding protein, an antibody or an antibody active fragment obtained by the above-described method for producing an antigen-binding protein, an antibody or an antibody active fragment.
In an eighth aspect, the present invention provides an antigen binding protein, antibody or antibody active fragment that specifically recognizes and/or binds to the RBD region of the S protein of SARS-Cov-2; the antigen binding protein, antibody or antibody active fragment comprises at least one heavy chain variable region; the heavy chain variable region has: CDR1 shown as SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6 or SEQ ID NO 7;
CDR2 shown as SEQ ID NO 8, SEQ ID NO 9, SEQ ID NO 10, SEQ ID NO 11, SEQ ID NO12 or SEQ ID NO 13; and
CDR3 shown as SEQ ID NO. 14, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 17, SEQ ID NO. 18 or SEQ ID NO. 19.
In some embodiments, the heavy chain variable region has: CDR2 as shown in SEQ ID NO. 2, CDR2 as shown in SEQ ID NO. 8 and CDR3 as shown in SEQ ID NO. 14.
In some embodiments, the heavy chain variable region has: CDR1 as shown in SEQ ID NO. 3, CDR2 as shown in SEQ ID NO. 9 and CDR3 as shown in SEQ ID NO. 15.
In some embodiments, the heavy chain variable region has: CDR1 shown in SEQ ID NO. 4, CDR2 shown in SEQ ID NO. 10 and CDR3 shown in SEQ ID NO. 16.
In some embodiments, the heavy chain variable region has: CDR1 shown in SEQ ID NO. 5, CDR2 shown in SEQ ID NO. 11 and CDR3 shown in SEQ ID NO. 17.
In some embodiments, the heavy chain variable region has: CDR1 as shown in SEQ ID NO. 6, CDR2 as shown in SEQ ID NO. 12 and CDR3 as shown in SEQ ID NO. 18.
In some embodiments, the heavy chain variable region has: CDR1 shown in SEQ ID NO. 7, CDR2 shown in SEQ ID NO. 13 and CDR3 shown in SEQ ID NO. 19.
In some embodiments, the heavy chain variable region has: the amino acid sequence shown as SEQ ID NO. 20 or conservative variant obtained by adding, deleting, replacing or modifying one or more amino acids in the amino acid sequence shown as SEQ ID NO. 20.
In some embodiments, the heavy chain variable region has: the amino acid sequence shown as SEQ ID NO. 21 or conservative variant obtained by adding, deleting, replacing or modifying one or more amino acids in the amino acid sequence shown as SEQ ID NO. 21.
In some embodiments, the heavy chain variable region has: the amino acid sequence shown as SEQ ID NO. 22 or conservative variant obtained by adding, deleting, replacing or modifying one or more amino acids in the amino acid sequence shown as SEQ ID NO. 22.
In some embodiments, the heavy chain variable region has: the amino acid sequence shown as SEQ ID NO. 23 or conservative variant obtained by adding, deleting, replacing or modifying one or more amino acids in the amino acid sequence shown as SEQ ID NO. 23.
In some embodiments, the heavy chain variable region has: the amino acid sequence shown as SEQ ID NO. 24 or conservative variant obtained by adding, deleting, replacing or modifying one or more amino acids in the amino acid sequence shown as SEQ ID NO. 24.
In some embodiments, the heavy chain variable region has: the amino acid sequence shown as SEQ ID NO. 25, or the conservative variant obtained by adding, deleting, replacing or modifying one or more amino acids in the amino acid sequence shown as SEQ ID NO. 25.
In some embodiments, the antigen binding protein, antibody or antibody active fragment comprises one of the heavy chain variable regions and lacks a light chain.
In some embodiments, the antibody is a nanobody and the antibody active fragment is a nanobody active fragment.
In a ninth aspect, the present invention provides a nucleotide sequence encoding an amino acid sequence as set forth in any one of SEQ ID NO 2 to SEQ ID NO 25 or an antigen binding protein, antibody or antibody active fragment as described above.
In some embodiments, the nucleotide sequence encoding the antigen binding protein, antibody or antibody active fragment is set forth in SEQ ID NO 26.
In some embodiments, the nucleotide sequence encoding the antigen binding protein, antibody or antibody active fragment is set forth in SEQ ID No. 27.
In some embodiments, the nucleotide sequence encoding the antigen binding protein, antibody or antibody active fragment is set forth in SEQ ID NO 28.
In some embodiments, the nucleotide sequence encoding the antigen binding protein, antibody or antibody active fragment is set forth in SEQ ID NO. 29.
In some embodiments, the nucleotide sequence encoding the antigen binding protein, antibody or antibody active fragment is set forth in SEQ ID NO 30.
In some embodiments, the nucleotide sequence encoding the antigen binding protein, antibody or antibody active fragment is set forth in SEQ ID NO 31.
In a tenth aspect, the present invention provides an expression vector comprising the nucleotide sequence described above.
In some embodiments, the expression vector is a phage expression vector, preferably a phage surface display screening vector.
In some embodiments, the expression vector further comprises a nucleotide sequence encoding the phage envelope protein pIII.
In an eleventh aspect, the present invention provides a virus exogenously transferred with the expression vector described above.
In some embodiments, the virus is a bacteriophage.
In a twelfth aspect, the present invention provides a host cell exogenously transformed with the expression vector described above, or infected with the virus described above.
In some embodiments, the host cell is e.
In a thirteenth aspect, the invention provides a method of expressing an antigen binding protein, antibody or antibody active fragment using a host cell as described above.
In a fourteenth aspect, the present invention provides an antigen binding protein, antibody or antibody active fragment obtained by expression using a host cell as described above.
In a fifteenth aspect, the present invention provides a humanized antigen binding protein, antibody or antibody active fragment obtained by humanizing the antigen binding protein, antibody or antibody active fragment described above.
In a sixteenth aspect, the present invention provides a protein conjugate comprising an antigen binding protein, antibody or antibody active fragment as described above or a humanised antigen binding protein, antibody or antibody active fragment as described above and a ligand.
In some embodiments, the ligand is selected from the group consisting of a radioisotope, a fluorophore, and a delivery vehicle.
In a seventeenth aspect, the present invention provides a pharmaceutical composition comprising an antigen binding protein, antibody or antibody active fragment as described above, a humanized antigen binding protein, antibody or antibody active fragment as described above, or a protein conjugate as described above.
In some embodiments, the pharmaceutical composition further comprises other active ingredients and/or adjuvants.
In an eighteenth aspect, the present invention provides a chimeric antigen receptor comprising an antigen binding protein, antibody or antibody active fragment as described above, a humanized antigen binding protein, antibody or antibody active fragment as described above.
In a nineteenth aspect, the present invention provides a chimeric antigen receptor T cell expressing the chimeric antigen receptor described above.
In a twentieth aspect, the present invention provides the use of an antigen binding protein, antibody or antibody active fragment as described above, an antibody library or polyclonal antibody as described above, an antigen specific antibody library as described above or a polyclonal antibody that specifically binds to an antigen, a nucleotide sequence as described above, an expression vector as described above, a virus as described above, a host cell as described above, a humanized antigen binding protein as described above, an antibody or antibody active fragment, a protein conjugate as described above, a pharmaceutical composition as described above, a chimeric antigen receptor as described above or a chimeric antigen receptor T cell as described above, for the manufacture of a medicament for the prevention of SARS-Cov-2 infection and/or the treatment of a disease caused by SARS-Cov-2 infection.
In a twenty-first aspect, the invention provides a kit for the in vitro detection of SARS-Cov-2 or the S protein of SARS-Cov-2 comprising an antigen binding protein, antibody or antibody active fragment as described above or a humanized antigen binding protein, antibody or antibody active fragment as described above.
In some embodiments, the antigen binding protein, antibody or antibody active fragment is labeled with a label. Preferably, the label is selected from the group consisting of an enzyme, a chemiluminescent group and an isotopic group.
In a twenty-second aspect, the present invention provides the use of an antigen binding protein, antibody or antibody active fragment as described above, a humanised antigen binding protein, antibody or antibody active fragment as described above, a protein conjugate as described above or a kit as described above for the in vitro detection of SARS-Cov-2 or the S protein of SARS-Cov-2.
In a twenty-third aspect, the present invention provides a method for detecting SARS-Cov-2 or S protein of SARS-Cov-2 in a sample using an antigen-binding protein, antibody or antibody active fragment as described above, a humanized antigen-binding protein, antibody or antibody active fragment as described above, a protein conjugate as described above, or a kit as described above.
In a twenty-fourth aspect, the present invention provides a contrast agent for detecting SARS-Cov-2 infection, comprising an antigen binding protein, antibody or antibody active fragment as described above or a humanized antigen binding protein, antibody or antibody active fragment as described above.
Compared with the prior art, the technical scheme provided by the invention has the following remarkable advantages: (1) The antibody obtained by the invention has low kd value and high affinity, and can specifically recognize and combine RBD regions; (2) The antibody is expected to be used as a new coronavirus detection tool and a new coronavirus S protein detection tool, and after the antibody is combined with an S protein RBD, the antibody is expected to block or destroy the membrane fusion between virus particles and host cells, so that the antibody is expected to treat diseases caused by the new coronavirus, and has potential clinical diagnosis and treatment values; (3) The antibody has the advantages of small relative molecular mass, high solubility, strong tissue permeability, good distributivity and rapid diffusion and metabolism, and is expected to make great contribution to the detection of new coronavirus or S protein on the surface of the new coronavirus and other related applications; (4) The antibody has simple structure, is easy to carry out genetic engineering transformation, has mature optimization strategy for enhancing the affinity of a single-domain antibody, prolonging the half-life period in vivo and coupling with other molecules for drug development, such as connecting radioactive isotopes, coupling transfer drugs, CART, fluorescence labeling high-resolution imaging and the like; (5) The heavy chain variable region sequence of the antibody has high homology with the human VH sequence, and the humanization of the single-domain antibody can be realized by a few amino acid mutations; (6) The antibody has high stability, acid and alkali pH resistance and high temperature resistance, can avoid the requirement that the conventional antibody needs low-temperature storage and transportation, and is beneficial to large-scale popularization and application; (7) The antibody provided by the invention can be well recombined and expressed in an escherichia coli expression system with low cost, the mass production cost is low, the yield can reach dozens of milligrams per liter of escherichia coli, the escherichia coli recombination and expression system is mature in technology, the quality control is simple, the production cost is favorably reduced, and the large-scale production is realized.
Drawings
FIG. 1 is a schematic diagram showing the result of detecting the affinity of the monoclonal antibody RBD _2A10 with an antigen;
FIG. 2 is a schematic diagram showing the result of detecting the affinity of the monoclonal antibody RBD _2B10 with the antigen;
FIG. 3 is a diagram showing the result of detecting the affinity of the monoclonal antibody RBD _2E2 with the antigen;
FIG. 4 is a schematic diagram showing the detection result of the affinity between the monoclonal antibody RBD _3D9 and the antigen;
FIG. 5 is a schematic diagram showing the result of detecting the affinity of the monoclonal antibody RBD _4G6 with the antigen;
FIG. 6 is a diagram showing the result of detecting the affinity of the monoclonal antibody RBD _4G8 for the antigen;
in each of the above figures, the left figure is the flow cytometry analysis result, wherein black is the incubation result of the antibody and the HEK293T cell not overexpressing the antigen, white is the incubation result of the antibody and the HEK293T cell overexpressing the antigen, the abscissa is the fluorescence intensity, and the ordinate is the normalized cell number; the right panel measures antibody affinity values for flow cytometry.
Detailed Description
The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.
Definition of
SARS-Cov-2: the international committee for virus classification names new coronaviruses (new coronaviruses for short).
S protein: the envelope of the new coronavirus particle is composed of Spike protein (S protein for short), E protein and M protein, wherein the S protein is one of main components on the surface of all coronaviruses; the total length of S protein on the surface of the new coronavirus is 1273 amino acids which can be divided into two parts of S1 and S2, and after the virus invades cells, the S protein is cut into an S1 subunit and an S2 subunit.
RBD area: the S1 subunit of the S protein of the new coronavirus mainly comprises an NTD region and an RBD region; wherein the RBD region is called receptor binding region and is S proteinThe area necessary for invasion of the host cell; the literature reports show that after the new coronavirus particles enter a human body, the S protein on the surfaces of the virus particles is combined with angiotensin converting enzyme (ACE 2) on the surface of a cytoplasmic membrane, and the RBD region of the S protein and the ACE2 have membrane fusion effect, so that the virus particles invade human cells.
kd value: the dissociation constant (kd) is a specific type of equilibrium constant that measures the tendency of a larger object to separate (dissociate) from another smaller component, and is the reciprocal of the association constant in mol/L (M) or nmol/L (nM). A smaller kd value indicates a stronger binding ability of the two substances.
Nanobodies: naturally light chain deficient antibodies found in the peripheral blood of camelids comprising only a heavy chain variable domain (VHH) and two conventional CH2 and CH3 domains, but which do not readily adhere to each other or even aggregate as artificially engineered single chain antibody fragments; the VHH structure which is cloned and expressed independently has the structural stability which is equivalent to that of the original heavy chain antibody and the binding activity with antigen, and is the minimum unit which is known to be combined with target antigen; the VHH crystal is 2.5nm, 4nm long and has a molecular weight of only 15KDa, so the VHH crystal is also called a Nanobody (Nb). Compared with the traditional animals such as mice, rabbits and the like which can only recognize the polypeptide with flat antigen surface, the immune system in the camelid animal body can recognize the complex spatial structure of the antigen surface and can generate the nano antibody with high specificity and high affinity.
According to the technical scheme of the invention, certain amino acids in the amino acid sequence can be conservatively substituted without changing the activity or function of the protein, see the following table 1:
TABLE 1
Furthermore, because of the degeneracy of bases, substitutions can be made to bases of a polynucleotide sequence without altering the activity or function of the polynucleotide sequence, see table 2 below:
TABLE 2
Example 1: preparation of antigens
In the prior art, the conventional method for preparing the antigen is to recombine, express and purify an RBD region of an S protein as the antigen and then immunize animals such as mice, rabbits, monkeys and the like. However, the above prior art has the following disadvantages: the immune system in the bodies of animals such as mice, rabbits, monkeys, etc. has limited capability and cannot generate a specific spatial structure for recognizing antigens; naturally, the S protein is a membrane protein located on the surface of viral particles, but the RBD region of the recombinantly expressed and purified S protein is not a membrane protein and is not present in the native state, and thus the resulting antibody is not necessarily able to correctly recognize the antigen.
Aiming at the RBD structure domain of the S protein of the new coronavirus, the method for preparing the antigen specifically comprises the following steps:
(1) <xnotran> , S RBD ( 319-541 , : RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNF) DNA pCaggs ; </xnotran>
(2) The plasmid is transfected into a HEK293T cell line by using liposome to be over-expressed, so that an S protein RBD region is displayed outside a cell membrane in a transmembrane protein mode;
(3) Collect about 4X 10 8 Cell is treated through ultrasonic crushing, homogenizing, ultracentrifugation and taking out cell membrane extract as antigen.
The DNA sequence for constructing the RBD region of the coding S protein adopted in the embodiment is specifically shown in SEQ ID NO:1, and specifically comprises the following steps:
CGGGTGCAGCCTACAGAGTCTATTGTGCGGTTCCCAAACATCACAAACCTGTGCCCTTTCGGCGAGGTGTTCAACGCCACCCGGTTCGCCTCTGTGTACGCCTGGAACCGGAAGCGGATCTCTAACTGCGTGGCCGACTACTCCGTGCTGTACAACTCCGCCTCTTTCTCTACATTCAAGTGCTACGGCGTGTCCCCTACAAAGCTGAACGACCTGTGCTTCACCAACGTGTACGCCGACTCTTTCGTGATTAGAGGCGACGAGGTGAGGCAGATTGCCCCCGGCCAGACAGGCAAGATCGCCGACTACAACTACAAGCTGCCCGACGACTTCACAGGCTGCGTGATCGCCTGGAACTCTAACAACCTGGACTCTAAGGTGGGCGGCAACTACAACTACCTGTACAGACTGTTCCGGAAGTCTAACCTGAAGCCATTCGAGAGGGACATTAGCACCGAGATTTACCAGGCCGGCTCTACCCCATGCAACGGCGTGGAGGGCTTCAACTGCTACTTCCCACTGCAGTCCTACGGCTTCCAGCCTACAAACGGCGTGGGCTACCAGCCTTACCGGGTGGTGGTGCTGTCTTTCGAGCTGCTCCACGCCCCCGCCACAGTGTGCGGCCCAAAGAAGAGCACAAACCTCGTGAAGAACAAGTGCGTGAACTTC
the RBD region of the S protein provided in this example is capable of being expressed and present on the surface of a cell membrane, approaching the native conformation and state of the S protein on the surface of a viral particle.
Example 2: alpaca immune injection
This example immunizes alpaca with the antigen prepared in example 1. The method comprises the following specific steps:
(1) The antigen prepared in example 1 was divided into 4 portions on average;
(2) 4 times of immunization is carried out on the alpaca in an accumulated way, the antigen is injected into the animal body subcutaneously, the first immunization is recorded as the first day, and the subsequent immunizations are respectively carried out on the 10 th day, the 19 th day and the 28 th day; on day 28, about 200mL of alpaca venous peripheral blood was collected before the fourth immunization injection, and on day 42, 14 days after the fourth immunization, about 300mL of alpaca venous peripheral blood was collected.
Compared with the traditional immunization technical scheme of animal antibodies such as mice and rabbits, the method provided by the embodiment collects a large amount of alpaca peripheral blood, and is favorable for obtaining highly diversified nano antibodies through subsequent screening.
Example 3: construction of antibody libraries
Two batches of alpaca venous peripheral blood collected in example 2 were used as raw materials to construct a highly diverse nanobody library. The method for treating the peripheral blood of the alpaca veins of two batches is the same, and specifically comprises the following steps:
(1) Separating lymphocytes from the peripheral blood of alpaca veins by using a density gradient centrifugation method;
(2) Extracting total mRNA of the lymphocyte and performing reverse transcription to obtain cDNA;
(3) Using proper DNA primer, using the cDNA as template, and obtaining VHH fragment of alpaca immunoglobulin IgG2 and IgG3 by Polymerase Chain Reaction (PCR) amplification, namely DNA fragment of nano antibody;
(4) Connecting the DNA of the VHH to a phage surface display screening vector to form a VHH-pIII fusion protein expression vector plasmid library; wherein pIII is a protein present on a bacteriophage surface flagellum;
(5) Transforming the DNA connecting product to TG1 competent bacteria by an electric transformation method, and collecting all colonies after proper culture, namely the nano antibody library of the alpaca.
Compared with the traditional method for separating the antibody from the serum or the lymphocyte of the animal such as the mouse, the rabbit and the like, the method can obtain and store all nano antibody fragments (namely the library) of the alpaca for a long time, and can continuously support the follow-up continuous screening and development of the nano antibody.
Example 4: phage surface display screening specific nano antibody
In this example, the nanobody library obtained in example 3 was used as a source, and the phage surface display screening was performed to obtain antigen-specific nanobodies. The method comprises the following specific steps:
(1) Taking a proper amount of the cryopreserved nano antibody library obtained in the embodiment 3, inoculating the cryopreserved nano antibody library to a bacterial culture medium, adding a proper amount of helper phage after proper culture, and continuously culturing under a proper amount of conditions;
(2) Extracting the amplified phage in the bacterial culture supernatant by a PEG-NaC method;
(3) Incubating the phage appropriately with the antigen; if the antigen is a cell membrane protein, the phage may be incubated with the enriched antigen-overexpressing cell whole or cell membrane extract; if the antigen is intracellular protein or secretory protein, the antigen can be fixed in a test tube, a micropore plate and other media in advance, and then incubated with the phage;
(4) Elutriation: discarding the phage, rinsing the antigen for a proper number of times by using PBS buffer solution, elutriating and removing the phage non-specifically combined with the antigen, and reserving the phage specifically combined with the antigen;
(5) And (3) elution: and (3) treating the phage specifically bound with the antigen by using an acidic glycine solution to dissociate and retain the phage from the antigen.
Thus, the bacteriophage expressing the specific nano antibody is obtained.
Example 5: construction of antigen-specific antibody libraries
This example uses the phage obtained in example 4 to construct an antigen-specific nanobody library. The method comprises the following specific steps:
(1) Infecting and culturing the phage with the specific nano antibody to Escherichia coli in a proper state, but not adding auxiliary phage;
(2) After the phage is completely infected, the specific nano antibody exists in Escherichia coli in the form of DNA plasmid, and all Escherichia coli are collected to obtain antigen-specific nano antibody library.
The library obtained in this example can be returned as a raw material to example 4 for phage surface display screening.
Example 6: obtaining of monoclonal antibody colonies
This example used the phage obtained in example 4 to obtain monoclonal nanobody colonies. The method comprises the following specific steps:
(1) Infecting the phage expressing the specific nano antibody with escherichia coli cultured to a proper state, but not adding auxiliary phage;
(2) After the bacteriophage is completely infected, the escherichia coli is evenly smeared on a bacterial culture dish for culture, and then the monoclonal colony containing the DNA plasmid of the nano antibody can be obtained.
Example 7: identification of Positive monoclonal antibodies
This example identifies the monoclonal colonies obtained in example 6. The method comprises the following specific steps:
(1) 6 groups of the monoclonal colonies are picked and cultured in a micropore plate respectively;
(2) Adding IPTG to induce expression of VHH-pIII (namely the fusion protein containing the nano antibody);
(3) Collecting bacterial culture supernatant containing the nano antibody, and incubating with the antigen;
(4) And detecting whether the monoclonal nano antibody is combined with the antigen or not by using a flow cytometry analysis method, namely whether the monoclonal nano antibody can be combined with the HEK293T cell over-expressing the RBD region of the S protein or not.
The results of measuring the affinity between the antibodies and the RBD region of the antigen S protein of the 6 groups of monoclonal colonies are shown in FIGS. 1 to 6, and the results of the affinity values kd are shown in Table 3 below.
Table 3: results of affinity assay
kd(nM) | |
RBD_2A10 | 590 |
RBD_2B10 | 1171 |
RBD_2E2 | 2.9 |
RBD_3D9 | 0.66 |
RBD_4G6 | 8 |
RBD_4G8 | 2678 |
From the above results, it is understood that the binding kd value of the antibody bound to the RBD region of the S protein of SARS-Cov-2 in the antibody obtained from the selected monoclonal colony in this example is 3000nM or less, preferably 1500nM or less, more preferably 600nM or less, more preferably 100nM or less, more preferably 10nM or less, more preferably 5nM or less, more preferably 1nM or less.
Respectively carrying out amplification culture on the 6 groups of monoclonal colonies, extracting DNA plasmids, carrying out DNA sequencing to obtain a nucleotide sequence of the antibody, and translating to obtain a complete amino acid sequence. Specifically, the amino acid sequences and nucleotide sequences corresponding to 6 groups of monoclonal antibody microbial colonies are specifically shown in tables 4 to 9 below:
table 4: amino acid sequence and nucleotide sequence of monoclonal antibody RBD _2A10
Table 5: amino acid sequence and nucleotide sequence of monoclonal antibody RBD _2B10
Table 6: amino acid sequence and nucleotide sequence of monoclonal antibody RBD _2E2
Table 7: amino acid sequence and nucleotide sequence of monoclonal antibody RBD _3D9
Table 8: amino acid sequence and nucleotide sequence of monoclonal antibody RBD _4G6
Table 9: amino acid sequence and nucleotide sequence of monoclonal antibody RBD _4G8
Example 8: small batch antibody production and preparation
The DNA plasmid of the nanobody obtained in example 7 was transformed into BL21 (DE 3) competent cells, and the monoclonal nanobody was expressed and purified in small batches with the aid of an E.coli expression system, with a batch yield of about several milligrams.
Although the invention has been described in detail hereinabove by way of general description, specific embodiments and experiments, it will be apparent to those skilled in the art that many modifications and improvements can be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.
SEQUENCE LISTING
<110> biosamping laboratory; huazhong university of science and technology
<120> specific antibody of new coronavirus S protein RBD region, preparation method and application thereof
<130> RYP2010929.3
<160> 31
<170> PatentIn version 3.5
<210> 1
<211> 669
<212> DNA
<213> SARS-Cov-2
<400> 1
cgggtgcagc ctacagagtc tattgtgcgg ttcccaaaca tcacaaacct gtgccctttc 60
ggcgaggtgt tcaacgccac ccggttcgcc tctgtgtacg cctggaaccg gaagcggatc 120
tctaactgcg tggccgacta ctccgtgctg tacaactccg cctctttctc tacattcaag 180
tgctacggcg tgtcccctac aaagctgaac gacctgtgct tcaccaacgt gtacgccgac 240
tctttcgtga ttagaggcga cgaggtgagg cagattgccc ccggccagac aggcaagatc 300
gccgactaca actacaagct gcccgacgac ttcacaggct gcgtgatcgc ctggaactct 360
aacaacctgg actctaaggt gggcggcaac tacaactacc tgtacagact gttccggaag 420
tctaacctga agccattcga gagggacatt agcaccgaga tttaccaggc cggctctacc 480
ccatgcaacg gcgtggaggg cttcaactgc tacttcccac tgcagtccta cggcttccag 540
cctacaaacg gcgtgggcta ccagccttac cgggtggtgg tgctgtcttt cgagctgctc 600
cacgcccccg ccacagtgtg cggcccaaag aagagcacaa acctcgtgaa gaacaagtgc 660
gtgaacttc 669
<210> 2
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
CDR1 of <223> monoclonal antibody RBD _2A10
<400> 2
Gly Phe Thr Phe Asp Asp Tyr Asp Met
1 5
<210> 3
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
CDR1 of <223> monoclonal antibody RBD _2B10
<400> 3
Gly Phe Thr Phe Asp Asp Tyr Thr Ile
1 5
<210> 4
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
CDR1 of <223> monoclonal antibody RBD _2E2
<400> 4
Gly Arg Thr Phe Ser Thr Tyr Ala Val
1 5
<210> 5
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> CDR1 of monoclonal antibody RBD _3D9
<400> 5
Gly Gly Thr Phe Ser Val Tyr Ser Met
1 5
<210> 6
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> CDR1 of monoclonal antibody RBD _4G6
<400> 6
Gly Arg Thr Phe Ser Thr Tyr Ala Met
1 5
<210> 7
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> CDR1 of monoclonal antibody RBD _4G8
<400> 7
Gly Ser Ile Phe Ser Ile Arg Ala Met
1 5
<210> 8
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
CDR2 of <223> monoclonal antibody RBD _2A10
<400> 8
Thr Cys Asp Gly Gly Thr Thr Tyr
1 5
<210> 9
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
CDR2 of <223> monoclonal antibody RBD _2B10
<400> 9
Ser Cys Ile Ser Ser Val Asp Gly Thr Thr His
1 5 10
<210> 10
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
CDR2 of <223> monoclonal antibody RBD _2E2
<400> 10
Leu Trp Asn Ser Gly Gly Thr Tyr
1 5
<210> 11
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> CDR2 of monoclonal antibody RBD _3D9
<400> 11
Ser Trp Asn Gly Glu Asn Ser Tyr
1 5
<210> 12
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> CDR2 of monoclonal antibody RBD _4G6
<400> 12
Ile Trp Ser Tyr Gly Gly Thr Tyr
1 5
<210> 13
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
CDR2 of <223> monoclonal antibody RBD _4G8
<400> 13
Thr Gly Gly Gly Ala Ser
1 5
<210> 14
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> CDR3 of monoclonal antibody RBD _2A10
<400> 14
Ala Lys Phe Ser Ala Asn Asp Pro Arg Glu
1 5 10
<210> 15
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<223> CDR3 of monoclonal antibody RBD _2B10
<400> 15
Ala Ala Thr Arg Gly Thr Tyr Tyr Asp Gly Ser Gln Tyr Leu Arg Asp
1 5 10 15
Pro Tyr Gly Met His
20
<210> 16
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<223> CDR3 of monoclonal antibody RBD _2E2
<400> 16
Ala Ala Asp Gly Ala Pro Ala Pro Tyr Thr Ile Val Glu Leu Asp Asp
1 5 10 15
Gly Glu Phe Tyr Thr
20
<210> 17
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<223> CDR3 of monoclonal antibody RBD _3D9
<400> 17
Ala Ala Ala Ser Thr Ser Ala Arg Gly Met Ser Val Leu Thr Pro Lys
1 5 10 15
Leu Gly
<210> 18
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<223> CDR3 of monoclonal antibody RBD _4G6
<400> 18
Ala Ala Asp Gly Ala Pro Ala Pro Tyr Thr Ile Val Glu Leu Asn Asp
1 5 10 15
Arg Gly Leu Tyr Lys
20
<210> 19
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> CDR3 of monoclonal antibody RBD _4G8
<400> 19
Ser Ala Asp Val Ile Glu Gly Asp Tyr Gly Thr Leu Leu Met Asp
1 5 10 15
<210> 20
<211> 118
<212> PRT
<213> Artificial Sequence
<220>
<223> amino acid sequence of monoclonal antibody RBD _2A10
<400> 20
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
20 25 30
Asp Met Ser Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Ile
35 40 45
Ser Val Ile Thr Cys Asp Gly Gly Thr Thr Tyr Tyr Ala Glu Ser Val
50 55 60
Lys Gly Arg Phe Ser Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
65 70 75 80
Leu Leu Ile Asp Ser Leu Lys Ser Glu Asp Thr Asp Val Tyr Tyr Cys
85 90 95
Ala Lys Phe Ser Ala Asn Asp Pro Arg Glu His Trp Gly Gln Gly Thr
100 105 110
Gln Val Thr Val Ser Ser
115
<210> 21
<211> 132
<212> PRT
<213> Artificial Sequence
<220>
<223> amino acid sequence of monoclonal antibody RBD _2B10
<400> 21
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
20 25 30
Thr Ile Gly Trp Phe Arg Gln Val Pro Gly Asn Glu Arg Glu Gly Gly
35 40 45
Glu Gly Val Ser Cys Ile Ser Ser Val Asp Gly Thr Thr His Tyr Ala
50 55 60
Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ala Lys Asn
65 70 75 80
Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val
85 90 95
Tyr Tyr Cys Ala Ala Thr Arg Gly Thr Tyr Tyr Asp Gly Ser Gln Tyr
100 105 110
Leu Arg Asp Pro Tyr Gly Met His Tyr Trp Gly Lys Gly Thr Gln Val
115 120 125
Thr Val Ser Ser
130
<210> 22
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> amino acid sequence of monoclonal antibody RBD _2E2
<400> 22
Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Thr Tyr
20 25 30
Ala Val Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val
35 40 45
Ala Ala Ile Leu Trp Asn Ser Gly Gly Thr Tyr Tyr Thr His Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Ala Asp Gly Ala Pro Ala Pro Tyr Thr Ile Val Glu Leu Asp Asp
100 105 110
Gly Glu Phe Tyr Thr Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser
115 120 125
Ser
<210> 23
<211> 126
<212> PRT
<213> Artificial Sequence
<220>
<223> amino acid sequence of monoclonal antibody RBD _2E2
<400> 23
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Gly Thr Phe Ser Val Tyr
20 25 30
Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Asp Arg Glu Phe Val
35 40 45
Ala Ala Ile Ser Trp Asn Gly Glu Asn Ser Tyr Tyr Thr Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Ser
65 70 75 80
Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Ser Cys
85 90 95
Ala Ala Ala Ser Thr Ser Ala Arg Gly Met Ser Val Leu Thr Pro Lys
100 105 110
Leu Gly Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser
115 120 125
<210> 24
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> amino acid sequence of monoclonal antibody RBD _4G6
<400> 24
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Thr Tyr
20 25 30
Ala Met Ser Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val
35 40 45
Ala Ala Ile Ile Trp Ser Tyr Gly Gly Thr Tyr Tyr Thr Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Ala Asp Gly Ala Pro Ala Pro Tyr Thr Ile Val Glu Leu Asn Asp
100 105 110
Arg Gly Leu Tyr Lys Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser
115 120 125
Ser
<210> 25
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> amino acid sequence of monoclonal antibody RBD _4G8
<400> 25
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Ser Ile Phe Ser Ile Arg
20 25 30
Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val
35 40 45
Ala Ala Ile Thr Gly Gly Gly Ala Ser Tyr Ala Asp Ser Val Lys Gly
50 55 60
Arg Leu Thr Ile Ser Thr Asp Asn Ala Asn Asn Thr Val Ser Leu Leu
65 70 75 80
Met Asn Ser Leu Lys Pro Glu Asp Ala Ala Val Tyr Tyr Cys Ser Ala
85 90 95
Asp Val Ile Glu Gly Asp Tyr Gly Thr Leu Leu Met Asp Leu Trp Gly
100 105 110
Arg Gly Thr Gln Val Thr Val Ser Ser
115 120
<210> 26
<211> 354
<212> DNA
<213> Artificial Sequence
<220>
<223> nucleotide sequence of monoclonal antibody RBD _2A10
<400> 26
gaggtgcagc tggtggagtc tgggggaggc ttggtgcagc ctggggggtc tctgagactc 60
tcctgtgcag cctctggatt cacttttgat gattatgaca tgagctgggt ccgacaggct 120
ccagagaagg ggctggagtg gatctctgtt atcacctgtg atggtggtac gacttactat 180
gcagaatccg tgaaaggccg attctccatc tccagagaca acgccaagaa cacgctgtat 240
ctgctaattg acagtctgaa atctgaggac acggacgtgt attactgcgc aaaattctcg 300
gctaacgacc caagggagca ctggggccag gggacccagg tcactgtctc ctct 354
<210> 27
<211> 396
<212> DNA
<213> Artificial Sequence
<220>
<223> nucleotide sequence of monoclonal antibody RBD _2B10
<400> 27
caggtgcagc tggtgcagtc tgggggaggc ttggtgcagc ctggggggtc tctgagactc 60
tcctgtgcag cctctggatt cactttcgat gattatacca taggctggtt ccgccaggtc 120
ccagggaatg agcgtgaggg gggtgagggg gtctcatgta ttagtagtgt tgatggtact 180
acacactatg cagagtccgt gaagggccga ttcaccatct ccagtgacaa cgccaagaac 240
acggtgtatc tgcaaatgaa cagcctgaaa cccgaggaca cggccgttta ttactgtgca 300
gcgaccaggg gtacatacta tgatggtagt caatacctta gggatccgta cggcatgcac 360
tactggggca aagggaccca ggtcactgtc tcctca 396
<210> 28
<211> 387
<212> DNA
<213> Artificial Sequence
<220>
<223> nucleotide sequence of monoclonal antibody RBD _2E2
<400> 28
caggtgcagc tgcaggagtc ggggggagga ttggtgcagg ctgggggctc tctgagactc 60
tcctgtgcag cctctggacg caccttcagt acctatgccg tgggctggtt ccgccaggct 120
ccaggaaagg agcgtgagtt tgttgcagct attctctgga atagtggtgg cacatattat 180
acacactccg tgaagggccg attcaccatc tccagagaca acgccaagaa cacggtgtat 240
ctgcaaatga acagcctgaa acctgaggac acggccgttt attattgtgc agcagatggg 300
gccccggcgc cctataccat agtggaattg gacgacggtg aattctatac ctactggggc 360
caggggaccc aggtcaccgt ctcctca 387
<210> 29
<211> 378
<212> DNA
<213> Artificial Sequence
<220>
<223> nucleotide sequence of monoclonal antibody RBD _3D9
<400> 29
caggtgcagc tggtgcagtc tgggggagga ttggtgcagg ctgggggctc tctgagactc 60
tcctgtacag cctctggtgg cacctttagt gtgtattcca tgggctggtt ccgccaggct 120
ccagggaagg accgtgagtt tgtagcagct atcagctgga atggtgaaaa ctcatactat 180
acagactccg tgaagggccg attcaccatc tccagagaca acgccaagaa cacggtgtcc 240
ctgcaaatga acagcctgaa acctgaggac acggccgttt attcttgtgc agcagcctcg 300
actagtgctc ggggcatgag tgtcctgacg ccgaaactgg gttcctgggg ccaggggacc 360
caggtcactg tctcctca 378
<210> 30
<211> 387
<212> DNA
<213> Artificial Sequence
<220>
<223> nucleotide sequence of monoclonal antibody RBD _4G6
<400> 30
caggtgcagc tggtgcagtc tgggggaggc ttggtgcagc ctggggggtc tctgagactc 60
tcctgtgcag cctctggacg caccttcagt acctatgcca tgagctggtt ccgccaggct 120
ccaggaaagg agcgtgagtt tgttgcagct attatctgga gttatggtgg cacatattat 180
acagactccg tgaagggccg attcaccatc tccagagaca acgccaagaa cacggtgtat 240
ctgcaaatga acagcctgaa acctgaggac acggccgttt attactgtgc agcagatggg 300
gccccggcgc cctatacgat agtggaactt aacgaccgtg gactctataa gtactggggc 360
caggggaccc aggtcactgt ctcctca 387
<210> 31
<211> 363
<212> DNA
<213> Artificial Sequence
<220>
<223> nucleotide sequence of monoclonal antibody RBD _4G8
<400> 31
gaggtgcagc tggtggagtc tgggggaggc ttggtgcagc ctggggggtc tctgagactc 60
tcctgtgcag tctctggaag catcttcagt atccgtgcca tgggctggta ccgccaggct 120
ccagggaagc agcgcgagtt ggtcgcagct attactggtg gtggtgcaag ctatgcggac 180
tccgtgaagg gccgactcac catctccaca gacaacgcca acaacacggt gtctctgctg 240
atgaacagcc tgaagcctga ggacgcggcc gtctattact gtagtgcaga cgtcattgag 300
ggcgactatg ggacgttgtt aatggattta tggggccggg ggacccaggt caccgtctcc 360
tca 363
Claims (26)
1. A nanobody or a nanobody active fragment that specifically recognizes and/or binds to the S protein RBD region of SARS-Cov-2, characterized in that it comprises a heavy chain variable region; the heavy chain variable region has:
CDR1 shown as SEQ ID NO. 2, CDR2 shown as SEQ ID NO. 8 and CDR3 shown as SEQ ID NO. 14;
or, CDR1 as shown in SEQ ID NO. 3, CDR2 as shown in SEQ ID NO. 9 and CDR3 as shown in SEQ ID NO. 15;
or, CDR1 as shown in SEQ ID NO. 4, CDR2 as shown in SEQ ID NO. 10 and CDR3 as shown in SEQ ID NO. 16;
or, CDR1 as shown in SEQ ID NO. 5, CDR2 as shown in SEQ ID NO. 11 and CDR3 as shown in SEQ ID NO. 17;
or, CDR1 as shown in SEQ ID NO. 6, CDR2 as shown in SEQ ID NO. 12 and CDR3 as shown in SEQ ID NO. 18;
or CDR1 as shown in SEQ ID NO. 7, CDR2 as shown in SEQ ID NO. 13 and CDR3 as shown in SEQ ID NO. 19.
2. The nanobody or nanobody active fragment according to claim 1, wherein it comprises a heavy chain variable region; the heavy chain variable region has:
an amino acid sequence shown as SEQ ID NO. 20;
or, the amino acid sequence shown as SEQ ID NO. 21;
or, the amino acid sequence shown as SEQ ID NO. 22;
or, the amino acid sequence shown as SEQ ID NO. 23;
or, the amino acid sequence shown as SEQ ID NO. 24;
or, the amino acid sequence shown as SEQ ID NO. 25.
3. A nucleic acid molecule encoding the nanobody or nanobody active fragment of claim 1 or 2.
4. An expression vector comprising the nucleic acid molecule of claim 3.
5. The expression vector of claim 4, wherein the expression vector is a phage expression vector.
6. The expression vector of claim 4, wherein the expression vector is a phage surface display screening vector.
7. The expression vector of claim 4, wherein the expression vector further comprises a nucleotide sequence encoding the phage envelope protein pIII.
8. A virus exogenously introduced with the expression vector of any one of claims 4 to 7.
9. The virus of claim 8, wherein the virus is a bacteriophage.
10. A host cell which has been exogenously introduced with an expression vector according to any one of claims 4 to 7 or infected with a virus according to claim 8 or 9.
11. The host cell of claim 10, wherein the host cell is e.
12. A method of expressing the nanobody or nanobody active fragment of claim 1 or 2 using the host cell of claim 10 or 11.
13. The nanobody or nanobody active fragment obtained by expression using the host cell of claim 10 or 11.
14. The humanized nanobody or nanobody active fragment of claim 1 or 2, which is obtained by humanization.
15. Protein conjugate, comprising a nanobody or nanobody active fragment according to claim 1 or 2 or a humanized nanobody or nanobody active fragment according to claim 14 and a ligand.
16. The protein conjugate of claim 15, wherein the ligand is selected from the group consisting of a radioisotope, a fluorophore, and a delivery vehicle.
17. Pharmaceutical composition comprising a nanobody or nanobody active fragment according to claim 1 or 2, a humanized nanobody or nanobody active fragment according to claim 14 or a protein conjugate according to claim 15 or 16.
18. The pharmaceutical composition of claim 17, wherein the pharmaceutical composition further comprises other active ingredients and/or adjuvants.
19. A chimeric antigen receptor comprising the nanobody or nanobody active fragment of claim 1 or 2 or the humanized nanobody or nanobody active fragment of claim 14.
20. A chimeric antigen receptor T cell expressing the chimeric antigen receptor of claim 19.
21. Use of the nanobody or nanobody active fragment according to claim 1 or 2, the nucleic acid molecule according to claim 3, the expression vector according to any one of claims 4 to 7, the virus according to claim 8 or 9, the host cell according to claim 10 or 11, the humanized nanobody or nanobody active fragment according to claim 14, the protein conjugate according to claim 15 or 16, the pharmaceutical composition according to claim 17 or 18, the chimeric antigen receptor according to claim 19 or the chimeric antigen receptor T cell according to claim 20 for the preparation of a medicament for the prevention of SARS-Cov-2 infection and/or for the treatment of a disease caused by SARS-Cov-2 infection.
22. A kit for in vitro detection of SARS-Cov-2 or the S protein of SARS-Cov-2, comprising the nanobody or nanobody active fragment of claim 1 or 2 or the humanized nanobody or nanobody active fragment of claim 14.
23. The kit of claim 22, wherein the nanobody or nanobody active fragment is labeled with a label.
24. The kit of claim 22, wherein the label is selected from the group consisting of an enzyme, a chemiluminescent group, and an isotopic group.
25. Use of the nanobody or nanobody active fragment of claim 1 or 2, the humanized nanobody or nanobody active fragment of claim 14, or the protein conjugate of claim 15 or 16 in the preparation of a kit for the in vitro detection of SARS-Cov-2 or S protein of SARS-Cov-2.
26. A contrast agent for detecting SARS-Cov-2 infection, comprising the nanobody or nanobody active fragment of claim 1 or 2 or the humanized nanobody or nanobody active fragment of claim 14.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011419890.1A CN114591425B (en) | 2020-12-07 | 2020-12-07 | Specific antibody of new coronavirus S protein RBD region and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011419890.1A CN114591425B (en) | 2020-12-07 | 2020-12-07 | Specific antibody of new coronavirus S protein RBD region and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114591425A CN114591425A (en) | 2022-06-07 |
CN114591425B true CN114591425B (en) | 2022-11-11 |
Family
ID=81812007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011419890.1A Active CN114591425B (en) | 2020-12-07 | 2020-12-07 | Specific antibody of new coronavirus S protein RBD region and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114591425B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116655786B (en) * | 2023-07-26 | 2023-10-27 | 中国人民解放军军事科学院军事医学研究院 | Broad-spectrum antibodies against SARS and SARS-CoV-2 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111057797A (en) * | 2020-01-19 | 2020-04-24 | 华中科技大学同济医学院附属同济医院 | Novel coronavirus 2019-nCoV real-time fluorescent quantitative PCR detection primer, probe, kit and method |
CN111825762A (en) * | 2020-06-17 | 2020-10-27 | 武汉华美生物工程有限公司 | Nano antibody of S protein RBD structure domain of anti SARS-COV-2 virus and its use |
CN112010967A (en) * | 2020-09-07 | 2020-12-01 | 康维众和(中山)生物药业有限公司 | Nano antibody for neutralizing toxicity of new coronavirus, preparation method and application thereof |
-
2020
- 2020-12-07 CN CN202011419890.1A patent/CN114591425B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111057797A (en) * | 2020-01-19 | 2020-04-24 | 华中科技大学同济医学院附属同济医院 | Novel coronavirus 2019-nCoV real-time fluorescent quantitative PCR detection primer, probe, kit and method |
CN111825762A (en) * | 2020-06-17 | 2020-10-27 | 武汉华美生物工程有限公司 | Nano antibody of S protein RBD structure domain of anti SARS-COV-2 virus and its use |
CN112010967A (en) * | 2020-09-07 | 2020-12-01 | 康维众和(中山)生物药业有限公司 | Nano antibody for neutralizing toxicity of new coronavirus, preparation method and application thereof |
Non-Patent Citations (3)
Title |
---|
An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction;Leo Hanke等;《Nature Communications》;20200904(第11期);第1-9页 * |
Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies;Daniel Wrapp等;《Cell》;20200528;第181卷(第5期);第1004-1016页 * |
新型冠状病毒S蛋白RBD肽段的原核表达与纯化;侯江厚等;《生物技术通讯》;20200530;第31卷(第03期);第292-296页 * |
Also Published As
Publication number | Publication date |
---|---|
CN114591425A (en) | 2022-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pandey | Hybridoma technology for production of monoclonal antibodies | |
TWI695010B (en) | Antigen binding molecules and methods of use thereof | |
CN107686520A (en) | Anti- PD L1 nano antibodies and its application | |
CN103992405B (en) | Anti-VEGF antibodies | |
CN116003598B (en) | Recombinant humanized monoclonal antibody targeting human GPRC5D and application thereof | |
CN111138537B (en) | Anti-human serum albumin antibody fragment, preparation method and application | |
US20210002699A1 (en) | Tim-3 nanobody, a preparation method thereof, and use thereof | |
WO2023216623A1 (en) | CAMEL-DERIVED HIGH-AFFINITY NANOANTIBODY AGAINST SARS-COV-2 α, γ, δ AND ο MUTANTS | |
CN113151186B (en) | Monoclonal antibody of anti-human CD271 and application | |
CN114591425B (en) | Specific antibody of new coronavirus S protein RBD region and preparation method and application thereof | |
CN114591424B (en) | Specific antibody of new coronavirus S protein NTD region and preparation method and application thereof | |
CN114591423B (en) | Specific antibody of new coronavirus N protein and preparation method and application thereof | |
US20190040119A1 (en) | Method for producing antibody | |
CN115286715B (en) | anti-CD3 nano antibody or antigen binding portion thereof and preparation method thereof | |
CN114685664B (en) | Single-domain antibody for resisting human B lymphocyte surface antigen CD20 and application thereof | |
CN106188298A (en) | A kind of Vsig4 nano antibody and epitope authentication method thereof and application | |
Desai et al. | Isolating anti-amyloid antibodies from yeast-displayed libraries | |
CN114591435B (en) | Specific antibody of pepsinogen II and preparation method and application thereof | |
CN114591436B (en) | Specific antibody of pepsinogen I and preparation method and application thereof | |
US11884741B2 (en) | Method for improving thermal stability of antibody and method for producing modified antibody | |
CN114763379B (en) | Specific antibody of new coronavirus S protein, preparation method and application thereof | |
CN114478761A (en) | Green fluorescent protein shark source nano antibody, preparation method and application thereof | |
TWI698643B (en) | Antibody and antibody fragments, kit and method for detecting miltenberger blood group antigen | |
CN110702913B (en) | Monoclonal antibody composition for quantitatively detecting coxiella burnetii I strain | |
CN116813765A (en) | Specific antibody of Rab8 protein and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |